Studies have shown that the first treatment you receive for cancer is by far the most important. On average, leukemia cancer patients who begin their treatment at Seattle Cancer Care Alliance (SCCA) have better survival rates than those who started treatment elsewhere.
At Seattle Cancer Care Alliance (SCCA), patients diagnosed with acute myelogenous leukemia (AML) receive state-of-the-art care from a team of specialists who focus almost exclusively on treating this disease.
If your condition requires a bone marrow transplant, you should know that the Fred Hutch Transplant Program at SCCA ranked first in outcomes in a multi-year study by the National Marrow Donor Program that measured one-year survival rates of patients at 122 transplant centers in the United States. The Hutch pioneered the use of bone marrow transplants as a treatment for blood diseases more than 40 years ago. Since then thousands of patients with leukemia have come here from around the world to receive bone marrow transplants. Bone marrow transplants have transformed leukemia and related cancers, once thought incurable, into highly treatable diseases.
SCCA was formed, in part, to bring promising new treatments to patients faster. For AML patients, this means more treatment options than they might find elsewhere, including the chance to participate in one of the dozen or more ongoing clinical studies for AML conducted at SCCA and its parent organizations, the Hutch and UW Medicine.